Publications by authors named "Tim Iveson"

Claim this Profile
S
Single-cell AI-based detection and prognostic and predictive value of DNA mismatch repair deficiency in colorectal cancer.
Marta Nowak, Faiz Jabbar, Ann-Katrin Rodewald, Luciana Gneo, Tijana Tomasevic, Tim Iveson

Cell Rep Med· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Standardizing data collection in adjuvant colon cancer trials: A consensus project from the IDEA and ACCENT international consortia and national experts.
Julien Taieb, Debora Basile, Jenny Seligmann, Guillem Argiles, Thierry André, Tim Iveson

Eur J Cancer· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic and Predictive Value of Immunoscore in Stage III Colorectal Cancer: Pooled Analysis of Cases From the SCOT and IDEA-HORG Studies.
Enric Domingo, Caroline Kelly, Jennifer Hay, Owen Sansom, Noori Maka, Tim Iveson

J Clin Oncol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
J
JAK/STAT3 represents a therapeutic target for colorectal cancer patients with stromal-rich tumors.
Kathryn A F Pennel, Phimmada Hatthakarnkul, Colin S Wood, Guang-Yu Lian, Sara S F Al-Badran, Tim Iveson

J Exp Clin Cancer Res· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multiplex analysis of intratumoural immune infiltrate and prognosis in patients with stage II-III colorectal cancer from the SCOT and QUASAR 2 trials: a retrospective analysis.
Anja L Frei, Anthony McGuigan, Ritik R A K Sinha, Faiz Jabbar, Luciana Gneo, Tim Iveson

Lancet Oncol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Accounting for intensity variation in image analysis of large-scale multiplexed clinical trial datasets.
Anja L Frei, Anthony McGuigan, Ritik Rak Sinha, Mark A Glaire, Faiz Jabbar, Tim J Iveson

J Pathol Clin Res· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A population-scale temporal case-control evaluation of COVID-19 disease phenotype and related outcome rates in patients with cancer in England (UKCCP).
Thomas Starkey, Maria C Ionescu, Michael Tilby, Martin Little, Emma Burke, Tim Iveson

Sci Rep· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of SARS-CoV-2 Spike Protein Antibody Vaccine Response With Infection Severity in Patients With Cancer: A National COVID Cancer Cross-sectional Evaluation.
Lennard Y W Lee, Michael Tilby, Thomas Starkey, Maria C Ionescu, Alex Burnett, Tim Iveson

JAMA Oncol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
COVID-19: Third dose booster vaccine effectiveness against breakthrough coronavirus infection, hospitalisations and death in patients with cancer: A population-based study.
Lennard Y W Lee, Maria C Ionescu, Thomas Starkey, Martin Little, Michael Tilby, Tim Iveson

Eur J Cancer· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Outcomes and Exploratory Analyses of the Randomized Phase III BILCAP Study.
John Bridgewater, Peter Fletcher, Daniel H Palmer, Hassan Z Malik, Raj Prasad, Tim Iveson

J Clin Oncol· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vaccine effectiveness against COVID-19 breakthrough infections in patients with cancer (UKCCEP): a population-based test-negative case-control study.
Lennard Y W Lee, Thomas Starkey, Maria C Ionescu, Martin Little, Michael Tilby, Tim Iveson

Lancet Oncol· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Three Versus Six Months of Adjuvant Doublet Chemotherapy for Patients With Colorectal Cancer: A Multi-Country Cost-Effectiveness and Budget Impact Analysis.
Catherine R Hanna, Jose A Robles-Zurita, Andrew Briggs, Andrea Harkin, Caroline Kelly, Tim Iveson

Clin Colorectal Cancer· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Second-line FOLFOX chemotherapy for advanced biliary tract cancer - Authors' reply.
Angela Lamarca, Daniel H Palmer, Harpreet Singh Wasan, Paul J Ross, Yuk Ting Ma, Tim Iveson

Lancet Oncol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial.
Angela Lamarca, Daniel H Palmer, Harpreet Singh Wasan, Paul J Ross, Yuk Ting Ma, Tim Iveson

Lancet Oncol· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Glasgow Microenvironment Score associates with prognosis and adjuvant chemotherapy response in colorectal cancer.
Peter G Alexander, Antonia K Roseweir, Kathryn A F Pennel, Hester C van Wyk, Arfon G M T Powell, Tim J Iveson

Br J Cancer· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patients' Preferences for 3 Months vs 6 Months of Adjuvant Chemotherapy for Colon Cancer.
Prunella Blinman, Andrew Martin, Michael Jefford, David Goldstein, David Boadle, Tim Iveson

JNCI Cancer Spectr· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes and survival following neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus: Inverse propensity score weighted analysis.
Philip H Pucher, Saqib A Rahman, Robert C Walker, Ben L Grace, Andrew Bateman, Tim Iveson

Eur J Surg Oncol· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Histological phenotypic subtypes predict recurrence risk and response to adjuvant chemotherapy in patients with stage III colorectal cancer.
Antonia K Roseweir, James H Park, Sanne Ten Hoorn, Arfon Gmt Powell, Susan Aherne, Tim J Iveson

J Pathol Clin Res· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant chemotherapy in colon cancer: state of the art and future perspectives.
Tim Iveson

Curr Opin Oncol· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study.
John N Primrose, Richard P Fox, Daniel H Palmer, Hassan Z Malik, Raj Prasad, Tim Iveson

Lancet Oncol· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patterns of progression, treatment of progressive disease and post-progression survival in the New EPOC study.
Siân A Pugh, Megan Bowers, Alexandre Ball, Stephen Falk, Meg Finch-Jones, Tim Iveson

Br J Cancer· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quality of life, long-term survivors and long-term outcome from the ABC-02 study.
John Bridgewater, Andre Lopes, Daniel Palmer, David Cunningham, Alan Anthoney, Tim Iveson

Br J Cancer· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomised, open-label phase II trial of afatinib versus cetuximab in patients with metastatic colorectal cancer.
Tamas Hickish, Jim Cassidy, David Propper, Ian Chau, Stephen Falk, Tim Iveson

Eur J Cancer· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial.
Gary Middleton, Paul Silcocks, Trevor Cox, Juan Valle, Jonathan Wadsley, Tim Iveson

Lancet Oncol· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial.
John Primrose, Stephen Falk, Meg Finch-Jones, Juan Valle, Derek O'Reilly, Tim Iveson

Lancet Oncol· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis